Does Hims Have Tirzepatide? What Sellers Must Know About This Market Shift

If you’ve been tracking the explosive growth of the telehealth and weight management market, you’ve likely stumbled upon a burning question from consumers and sellers alike: does Hims have tirzepatide? As a cross-border e-commerce seller or online store owner, understanding the product lineup of major direct-to-consumer (DTC) brands like Hims & Hers isn’t just curiosity—it’s a strategic necessity. The answer to this question directly influences your inventory decisions, competitor analysis, and even your keyword strategy for platforms like Amazon, Shopify, or your own branded store.

In this article, we’ll break down the facts: does Hims offer tirzepatide, why this matters to your business, and how you can leverage this knowledge to stay ahead in the highly competitive wellness and pharmacy e-commerce niche. We’ll explore the current product landscape, regulatory nuances, and what the future holds for GLP-1 receptor agonists in the DTC space.

The Short Answer: Does Hims & Hers Actually Sell Tirzepatide?

As of the latest updates in 2025, Hims & Hers does not currently offer tirzepatide (the active ingredient in Mounjaro and Zepbound). While the brand has aggressively expanded into weight loss and metabolic health—primarily through compounded semaglutide formulations—tirzepatide has not been added to their product roster. However, this answer comes with important nuances that every cross-border seller should understand.

Here’s the reality: Hims & Hers has built its weight loss program around compounded GLP-1 medications, specifically semaglutide (the same active ingredient in Ozempic and Wegovy). Tirzepatide, produced by Eli Lilly under the brand names Mounjaro (for diabetes) and Zepbound (for weight loss), remains patent-protected and is primarily available through traditional healthcare providers and specialty pharmacies. The question “does hims have tirzepatide” often pops up because consumers are searching for the newest and most potent options.

Why doesn’t Hims stock it? The primary reason is supply chain complexity and regulatory risk. Tirzepatide is still under patent, and compounding it requires specific FDA permissions that differ from semaglutide. Hims has instead focused on semaglutide, which has a more established compounding supply chain and lower price point for consumers.

Why “Does Hims Have Tirzepatide” Matters for E-Commerce Sellers

You might be thinking: “I’m a seller, not a patient. Why should I care about a single brand’s product lineup?” Here’s the truth: consumer search behavior shapes the entire e-commerce ecosystem. The phrase “does hims have tirzepatide” is being searched thousands of times per month. Every search represents a potential customer who is either:

• Comparing brands before making a purchase decision
• Looking for alternatives if Hims doesn’t carry what they need
• Researching price points across different platforms
• Seeking compounded or generic versions of popular weight loss drugs

As a seller, you can capitalize on these search intents. For example, if you sell health-related products on Amazon, targeting long-tail keywords like “best alternatives to hims tirzepatide” or “where to buy tirzepatide online” (where legally permissible) can drive targeted traffic to your listings. Understanding that Hims does not have tirzepatide allows you to position your own products as viable solutions—whether that’s through affiliate marketing, supplement bundles, or educational content on your Shopify store.

The GLP-1 Boom: Market Data Every Seller Should Know

To fully grasp why the question “does hims have tirzepatide” is so important, let’s look at the numbers. The global GLP-1 receptor agonist market was valued at over $40 billion in 2024 and is projected to exceed $100 billion by 2030. This includes drugs like semaglutide, liraglutide, and—you guessed it—tirzepatide.

Here’s what stands out for e-commerce entrepreneurs:

• Tirzepatide has been shown in clinical trials to produce up to 20-25% body weight reduction, outperforming semaglutide’s 15% average. This makes it a highly desired product.
• Google searches for “tirzepatide” grew by over 400% year-over-year in 2024, driven by consumer demand and media coverage.
• Hims & Hers recently reported that their weight loss program attracted over 100,000 new subscribers in Q3 2024 alone, primarily for semaglutide. This indicates massive demand that could shift to tirzepatide if it becomes available.

For sellers, this data translates into a clear message: The demand for tirzepatide is real and growing. If you can legally and ethically offer products that support tirzepatide users (e.g., vitamins, meal plans, or tracking apps), or if you’re in the pharmaceutical space, you need to watch for when Hims—or similar platforms—“flip the switch” and start offering tirzepatide.

What Hims Offers Instead: The Semaglutide Strategy

Since Hims does not have tirzepatide, understanding their actual product suite is crucial for competitive analysis. Hims & Hers has built a strong weight loss vertical around:

1. Compounded Semaglutide – Offered through their telehealth platform at a significantly lower price than branded Ozempic or Wegovy (often $199-299/month vs. $900+).
2. Lifestyle Coaching – Nutritional and behavioral support included with subscriptions.
3. Over-the-Counter Supplements – Vitamins, hydration powders, and appetite control products that complement their weight loss programs.

For e-commerce sellers, this product mix reveals a pattern: Hims focuses on affordability and accessibility. They’ve democratized access to semaglutide, but they haven’t yet tackled tirzepatide. This could be due to patent restrictions, pricing constraints, or simply a strategic focus on semaglutide’s proven demand.

Pro Tip for Sellers: If you run a supplement store on Shopify, consider creating a “Tirzepatide Support Kit” category. Include items like protein powders, electrolyte mixes, anti-nausea supplements, and portion control tools. Consumers who are using tirzepatide from other sources will search for these—and since Hims doesn’t offer tirzepatide, they won’t be a direct competitor in this niche.

Regulatory and Patent Considerations: Why Hims Can’t Just Add Tirzepatide

One of the most common questions we hear from sellers is: “If tirzepatide is so popular, why doesn’t Hims just stock it?” The answer lies in the complex world of drug patents and FDA regulations.

Tirzepatide is protected by exclusive patents held by Eli Lilly until at least 2036. While compounding pharmacies can produce “essentially a copy” of a drug during shortages, this is a legally gray area. Hims has faced scrutiny for their compounding practices with semaglutide, and adding tirzepatide could expose them to higher legal risks.

Moreover, the FDA has designated tirzepatide as a drug with “chronic shortage” in certain doses, which does allow for compounding—but the demand far exceeds supply. Hims would need to secure reliable, compliant